BRPI0415714A - uso de cci-779, composição farmacêutica e embalagem farmacêutica - Google Patents

uso de cci-779, composição farmacêutica e embalagem farmacêutica

Info

Publication number
BRPI0415714A
BRPI0415714A BRPI0415714-1A BRPI0415714A BRPI0415714A BR PI0415714 A BRPI0415714 A BR PI0415714A BR PI0415714 A BRPI0415714 A BR PI0415714A BR PI0415714 A BRPI0415714 A BR PI0415714A
Authority
BR
Brazil
Prior art keywords
cci
pharmaceutical
pharmaceutical composition
packaging
pharmaceutical packaging
Prior art date
Application number
BRPI0415714-1A
Other languages
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415714(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of BRPI0415714A publication Critical patent/BRPI0415714A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"USO DE CCI-779, COMPOSIçãO FARMACêUTICA E EMBALAGEM FARMACêUTICA". A presente invenção refere-se ao uso de 42-éster de rapamicina com ácido 3-hidróxi-2-(hidróximetil)-2-metilpropiónico (CCI-779) no tratamento ou inibição de linfoma de célula do manto.
BRPI0415714-1A 2003-11-04 2004-10-28 uso de cci-779, composição farmacêutica e embalagem farmacêutica BRPI0415714A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04
PCT/US2004/035900 WO2005046681A1 (en) 2003-11-04 2004-10-28 Cci-779 for treating mantle cell lymphoma

Publications (1)

Publication Number Publication Date
BRPI0415714A true BRPI0415714A (pt) 2006-12-19

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415714-1A BRPI0415714A (pt) 2003-11-04 2004-10-28 uso de cci-779, composição farmacêutica e embalagem farmacêutica

Country Status (30)

Country Link
US (2) US20050113403A1 (pt)
EP (1) EP1682131B9 (pt)
JP (1) JP4856548B2 (pt)
KR (1) KR101387988B1 (pt)
CN (1) CN1901906B (pt)
AR (1) AR046194A1 (pt)
AT (1) ATE373477T1 (pt)
AU (1) AU2004289213B2 (pt)
BR (1) BRPI0415714A (pt)
CA (1) CA2543665C (pt)
CO (1) CO5690605A2 (pt)
CR (1) CR8383A (pt)
DE (1) DE602004009098T2 (pt)
DK (1) DK1682131T3 (pt)
EC (1) ECSP066600A (pt)
ES (1) ES2291954T3 (pt)
GT (1) GT200400224A (pt)
IL (2) IL175128A0 (pt)
MY (1) MY136436A (pt)
NO (1) NO20062271L (pt)
PA (1) PA8616601A1 (pt)
PE (1) PE20051000A1 (pt)
PL (1) PL1682131T3 (pt)
PT (1) PT1682131E (pt)
RU (1) RU2358731C2 (pt)
SA (1) SA04250375B1 (pt)
TW (1) TW200517116A (pt)
UA (1) UA83697C2 (pt)
WO (1) WO2005046681A1 (pt)
ZA (1) ZA200603533B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US20080207644A1 (en) * 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2313983T3 (es) * 2000-09-19 2009-03-16 Wyeth Esteres hidrosolubles de rapamicina.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
IL158800A0 (en) 2001-06-01 2004-05-12 Wyeth Corp Antineoplastic combinations
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
PT1553940E (pt) * 2002-07-30 2008-05-09 Wyeth Corp Formulações parentéricas contendo um hidroxi-éster de rapamicina
EP1615640B1 (en) * 2003-04-22 2007-01-24 Wyeth Antineoplastic combinations
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
CN1901906A (zh) 2007-01-24
EP1682131A1 (en) 2006-07-26
RU2358731C2 (ru) 2009-06-20
EP1682131B9 (en) 2009-03-25
HK1088241A1 (en) 2006-11-03
DE602004009098D1 (de) 2007-10-31
ECSP066600A (es) 2006-10-25
DK1682131T3 (da) 2008-01-28
AU2004289213A1 (en) 2005-05-26
JP4856548B2 (ja) 2012-01-18
CN1901906B (zh) 2011-11-16
UA83697C2 (ru) 2008-08-11
ATE373477T1 (de) 2007-10-15
ZA200603533B (en) 2007-07-25
GT200400224A (es) 2005-06-06
KR20060111559A (ko) 2006-10-27
CO5690605A2 (es) 2006-10-31
US20110184010A1 (en) 2011-07-28
CA2543665C (en) 2009-07-14
CR8383A (es) 2006-10-04
AR046194A1 (es) 2005-11-30
US8507518B2 (en) 2013-08-13
EP1682131B1 (en) 2007-09-19
ES2291954T3 (es) 2008-03-01
MY136436A (en) 2008-10-31
PL1682131T3 (pl) 2008-02-29
TW200517116A (en) 2005-06-01
IL220080A0 (en) 2012-07-31
JP2007510721A (ja) 2007-04-26
SA04250375B1 (ar) 2007-08-13
PA8616601A1 (es) 2006-06-02
KR101387988B1 (ko) 2014-04-22
PT1682131E (pt) 2007-11-08
DE602004009098T2 (de) 2008-06-26
RU2006119451A (ru) 2007-12-20
NO20062271L (no) 2006-07-21
IL175128A0 (en) 2008-04-13
WO2005046681A1 (en) 2005-05-26
PE20051000A1 (es) 2006-02-03
CA2543665A1 (en) 2005-05-26
AU2004289213B2 (en) 2010-08-26
US20050113403A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0608690B8 (pt) uso de uma composição antimicrobiana
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
NO20064130L (no) Antineoplastiske kombinasjoner av CCI-779 og rituximab
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
BRPI0409632A (pt) combinações antineoplásticas
ES2421455T3 (es) Uso de derivados de rapamicina en vasculopatías
BRPI0408024A (pt) combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase
DE60222931D1 (de) Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
BR0211769A (pt) Combinações antineoplásicas
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
BR0210205A (pt) Antiinfecciosos
BR9707739A (pt) Utilizacão de compostos orgânicos
TR200100805T2 (tr) Tetrahidropiridoeterler
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
BRPI0518406A2 (pt) composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
EP2772254A3 (en) Novel Antibacterial Agents
PT920421E (pt) Derivados de isoxazolina uteis como agentes antimicrobianos
ES2195397T3 (es) Quinazolin-2,4-dionas sustituidas en posicion 7 utiles como agentes antibacterianos.
AR034071A1 (es) Combinaciones antineoplasicas
BRPI0415714A (pt) uso de cci-779, composição farmacêutica e embalagem farmacêutica
ATE372986T1 (de) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridon s als antimikrobielle mittel
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
ATE418613T1 (de) Antimikrobielle zusammensetzungen
CR8162A (es) Piridinylanilides

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]